An Open-Label, Flexible-Dose Study of Retigabine Immediate Release (IR) as Adjunctive Therapy to Specified Monotherapy Antiepileptic Treatments in Adults With Partial -Onset Seizures.

Trial Profile

An Open-Label, Flexible-Dose Study of Retigabine Immediate Release (IR) as Adjunctive Therapy to Specified Monotherapy Antiepileptic Treatments in Adults With Partial -Onset Seizures.

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Aug 2015

At a glance

  • Drugs Retigabine (Primary)
  • Indications Complex partial epilepsy; Partial epilepsies
  • Focus Registrational; Therapeutic Use
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 31 Aug 2012 Planned End Date changed from 1 Jul 2013 to 1 Dec 2012 as reported by ClinicalTrials.gov (Parent trial: NCT01227902).
    • 31 Aug 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov (Parent trial: NCT01227902).
    • 22 Feb 2012 Planned patient number changed from changed from 212 to 235 as reported by European Clinical Trials Database. (Parent trial; EudraCT2009-017744-14)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top